Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
Phase 3
Recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 459
- Registration Number
- NCT05772208
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Colorectal CancerMicrosatellite Stable Colorectal Carcinoma
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05771181
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases
Not Applicable
Recruiting
- Conditions
- Nasopharyngeal CarcinomaLiver Metastases
- Interventions
- Procedure: Hepatectomy
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 55
- Registration Number
- NCT05771025
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
Not Applicable
Recruiting
- Conditions
- Metastatic Esophageal Squamous Cell Carcinoma
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT05760391
- Locations
- 🇨🇳
Fudan University Shanghai cancer center, Shanghai, China
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Phase 3
Recruiting
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 223
- Registration Number
- NCT05760378
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 145
- Registration Number
- NCT05759572
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT05759546
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Ovarian Clear Cell Carcinoma
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT05759312
Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study
Phase 2
Recruiting
- Conditions
- Colorectal Liver Metastasis
- Interventions
- Combination Product: HAIC-FOLFOX combined with Sintilimab and Regorafenib
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT05753163
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Phase 2
Recruiting
- Conditions
- Triple-negative Breast Cancer
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT05749588
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath